Amidst the rapid evolution of DNA sequencing technologies in past years, the industry has been working tirelessly to make genomics more accessible. Since the Human Genome Project, which saw scientists from six countries coming together to map the first human genome at nearly $3 billion over 13 years, the cost of whole-genome sequencing has fallen to less than $1,000 today. Yet, the quest to produce larger amounts of short- and long-read data in a shorter span of time and at an even lower cost continues.
International Vaccine Institute – IVI – will locate its European office in Stockholm
Latest NewsThe International Vaccine Institute, IVI, which is associated with the WHO and UN, will locate its European office in Stockholm. To date, the institute is only located in the host country of South Korea.
Abliva decides on a SEK200m financing to fund Phase 2/3 study
Latest NewsThe financing (around €19m) shall fully fund the commencement of a potentially pivotal/registrational Phase 2/3 study for KL1333 and its progression to the outcome of a key interim analysis.
Transine Therapeutics Ltd closes £13.7m seed financing
Latest NewsTransine Therapeutics Ltd has added £4.6m from lead investor Epidarex Capital and the Dementia Discovery Fund (DDF) to its £9.1m seed funding led by Takeda Ventures and DDF.
MGI turns a new page in the human genome era with ultra-high throughout DNBSEQ-T7 sequencer*
Sponsored PublicationsAmidst the rapid evolution of DNA sequencing technologies in past years, the industry has been working tirelessly to make genomics more accessible. Since the Human Genome Project, which saw scientists from six countries coming together to map the first human genome at nearly $3 billion over 13 years, the cost of whole-genome sequencing has fallen to less than $1,000 today. Yet, the quest to produce larger amounts of short- and long-read data in a shorter span of time and at an even lower cost continues.
Orphan drug developer Minoryx raises €51m
Latest NewsMinoryx Therapeutics SL has closed a €51m financing, including Series C equity financing and complementary bank debt to commercialise X-ALD drug leriglitazone.
G7 heads call for decarbonisation of industry
Latest NewsG7 Climate, Energy and Environment Ministers have announced a wide range of actions to tackle the triple global crisis of climate change, biodiversity loss and pollution".
Anti-ID antibody production
ProductsAn anti-idiotypic antibody (anti-ID Ab) can recognise and bind to the idiotypic center of another antibody. Anti-idiotype antibodies are widely used in therapeutic drug development, such as immunogenicity assessments, pharmacokinetic/pharmacodynamics (PK/PD) studies, and vaccine development.
Ellipses Pharma licences SRB22 from SunRock Biopharma
Latest NewsEllipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein set to eliminate solid tumours.
The silent pandemic is not silent anymore
OpinionCOVID-19 is the acute pandemic, while antimicrobial resistance (AMR) is a silent, pandemic. New data makes the AMR pandemic visible, with the first global study of AMR estimating that 1.27 million people die from AMR every year, making AMR the 12th-leading cause of death globally.
Evotec signs contracts with Almirall and Sernova
Latest NewsHamburg-based CRO Evotec SE has inked a drug development partnership with Spanish Almirall SA in dematology.